Literature DB >> 9331427

Role of c-Src tyrosine kinase in EGF-induced mitogenesis.

A P Belsches1, M D Haskell, S J Parsons.   

Abstract

c-Src, the prototype of the cytoplasmic, membrane-associated,non-receptor tyrosine kinases, is a co-transducer of mitogenic signals emanating from a number of tyrosine kinase polypeptide growth factor receptors. Examples of such receptors include those that bind the platelet-derived growth factor (PDGF), colony stimulating factor-1 (CSF-1), and epidermal growth factor (EGF). Investigations into the mechanisms by which c-Src contributes to receptor signaling suggest that interactions between the two proteins are bidirectional, i.e., that c-Src can bind, phosphorylate, and activate the receptor, and vice versa. The consequences of these interactions appear to be enhanced phosphorylation of specific substrates. Delineating which cellular proteins are substrates of which tyrosine kinase and determining the consequences of tyrosine phosphorylation on the function of specific substrates are the goals of current investigations. Utilizing the murine C3H10T fibroblast model, in which a panel of wild type and mutant c-Src/EGF receptor overexpressors has been studied for temporal and spatial second messenger responses to EGF, distinctions between substrates of c-Src and the EGF receptor and the effects of tyrosine phosphorylation on substrate function are beginning to emerge. In the 10T model, preferred substrates of c-Src are almost exclusively comprised of those molecules that associate with the actin cytoskeleton or with focal adhesions, such as cortactin, p190RhoGAP, and p130CAS, while preferred substrates of the EGF receptor include the receptor itself, SHC, phospholipase C-gamma and p62DOK. While the major mitogenic signaling pathway is thought to proceed directly from the receptor (through SHC/GRB2/SOS/Ras/Raf/MEK/MAPkinase/Elk1), more evidence is accumulating to suggest that proteins involved in regulating the actin cytoskeleton (such as c-Src substrates) also participate in mitogenesis, either as unique transducers of growth signals and/or as monitors of anti-apoptotic conditions (substratum attachment). How c-Src may contribute to the EGF mitogenic response through tyrosine phosphorylation of or association with its specific substrates is discussed. Cellular Src (c-Src), prototype for a family of intracellular membrane-associated tyrosine kinases, is required for mitogenesis initiated by multiple growth factor receptors, including the receptors for epidermal growth factor (EGF), platelet-derived growth factor (PDGF), colony stimulating factor-1 (CSF-1), and the basic fibroblast growth factor (bFGF). C-Src is also overexpressed and/or activated in many of the same human carcinomas that overexpress members of the EGF receptor (EGFR) family, suggesting that the two types of tyrosine kinases can cooperate during the genesis of human tumors. This review focuses on the role of c-Src in EGF-dependent mitogenesis and tumorigenesis, i.e., on the interactions between c-Src and the receptor and on identification of c-Src substrates, their functions, and the effects of tyrosine phosphorylations on their functions. A synopsis of other mitogenic and signaling systems is also included for comparative purposes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331427     DOI: 10.2741/a208

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  37 in total

Review 1.  Role of Forkhead Box Class O proteins in cancer progression and metastasis.

Authors:  Chang Geun Kim; Hyemin Lee; Nehal Gupta; Sharavan Ramachandran; Itishree Kaushik; Sangeeta Srivastava; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2017-08-01       Impact factor: 15.707

2.  SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Authors:  Won Gu Kim; Celine J Guigon; Laura Fozzatti; Jeong Won Park; Changxue Lu; Mark C Willingham; Sheue-yann Cheng
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

3.  The Src kinase Yes is activated in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters, but not pancreatic growth factors, which stimulate its association with numerous other signaling molecules.

Authors:  Veronica Sancho; Bernardo Nuche-Berenguer; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2012-05-19

Review 4.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Activation of Lyn tyrosine kinase through decreased membrane cholesterol levels during a change in its membrane distribution upon cell detachment.

Authors:  Takao Morinaga; Kohei Abe; Yuji Nakayama; Noritaka Yamaguchi; Naoto Yamaguchi
Journal:  J Biol Chem       Date:  2014-08-07       Impact factor: 5.157

6.  Cdc42 and Tks5: a minimal and universal molecular signature for functional invadosomes.

Authors:  Julie Di Martino; Lisa Paysan; Caroline Gest; Valérie Lagrée; Amélie Juin; Frédéric Saltel; Violaine Moreau
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

Review 7.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

8.  Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

Authors:  Deric L Wheeler; Mari Iida; Tim J Kruser; Meghan M Nechrebecki; Emily F Dunn; Eric A Armstrong; Shyhmin Huang; Paul M Harari
Journal:  Cancer Biol Ther       Date:  2009-04-22       Impact factor: 4.742

Review 9.  The insulin-like growth factor (IGF) receptor type 1 (IGF1R) as an essential component of the signalling network regulating neurogenesis.

Authors:  Alexander Annenkov
Journal:  Mol Neurobiol       Date:  2009-08-29       Impact factor: 5.590

10.  The formin-homology protein SmDia interacts with the Src kinase SmTK and the GTPase SmRho1 in the gonads of Schistosoma mansoni.

Authors:  Thomas Quack; Jürgen Knobloch; Svenja Beckmann; Jérome Vicogne; Colette Dissous; Christoph G Grevelding
Journal:  PLoS One       Date:  2009-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.